Esther Frimpong

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Edward Agyare · 8 shared papers, 2022–2026 · strength 1.70
   • Paper Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expre… DOI 10.1016/j.ijpx.2026.100544↗
   • Paper Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. DOI 10.1177/15330338261468414↗
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
2. Raviteja Bulusu · 7 shared papers, 2022–2026 · strength 1.51
   • Paper Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expre… DOI 10.1016/j.ijpx.2026.100544↗
   • Paper Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. DOI 10.1177/15330338261468414↗
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
3. Bo Han · 6 shared papers, 2022–2024 · strength 1.07
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
   • Paper Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African … DOI 10.1016/j.jnma.2023.01.008↗
   • Paper Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. DOI 10.1186/s12885-023-10928-w↗
4. Joy C. Okoro · 4 shared papers, 2023–2026 · strength 1.03
   • Paper Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expre… DOI 10.1016/j.ijpx.2026.100544↗
   • Paper Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. DOI 10.1177/15330338261468414↗
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
5. Andriana Inkoom · 5 shared papers, 2022–2024 · strength 0.88
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
   • Paper Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. DOI 10.1186/s12885-023-10928-w↗
   • Paper Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. DOI 10.3390/ijms24054288↗
6. Nkafu Bechem Ndemazie · 5 shared papers, 2022–2024 · strength 0.88
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
   • Paper Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. DOI 10.1186/s12885-023-10928-w↗
   • Paper Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. DOI 10.3390/ijms24054288↗
7. Saunjoo Yoon · 2 shared papers, 2026 · strength 0.63
   • Paper Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expre… DOI 10.1016/j.ijpx.2026.100544↗
   • Paper Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. DOI 10.1177/15330338261468414↗
8. Sherise Chantell Rogers · 3 shared papers, 2023–2024 · strength 0.58
   • Paper Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-… DOI 10.1016/j.ejps.2024.106754↗
   • Paper Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African … DOI 10.1016/j.jnma.2023.01.008↗
   • Paper Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. DOI 10.3390/ijms24054288↗
9. Jose Gilberto Trevino · 3 shared papers, 2022–2023 · strength 0.49
   • Paper Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. DOI 10.1186/s12885-023-10928-w↗
   • Paper Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for panc… DOI 10.1186/s12885-022-10449-y↗
   • Paper Application of modified gemcitabine-loaded solid lipid nanoparticle in the treatment of pancreatic cancer patient-deriv… DOI 10.21203/rs.3.rs-1777458/v1↗
10. Sunil Krishnan · 1 shared paper, 2026 · strength 0.32
    • Paper Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expre… DOI 10.1016/j.ijpx.2026.100544↗
11. John M. Allen · 1 shared paper, 2023 · strength 0.18
    • Paper Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African … DOI 10.1016/j.jnma.2023.01.008↗
12. Guettchina Telisnor · 1 shared paper, 2023 · strength 0.18
    • Paper Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African … DOI 10.1016/j.jnma.2023.01.008↗
13. Thomas J. George · 1 shared paper, 2023 · strength 0.18
    • Paper Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African … DOI 10.1016/j.jnma.2023.01.008↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.